Tue.Apr 02, 2024

article thumbnail

Scientists link certain gut bacteria to lower heart disease risk

Broad Institute

Scientists link certain gut bacteria to lower heart disease risk By Allessandra DiCorato April 2, 2024 Breadcrumb Home Scientists link certain gut bacteria to lower heart disease risk Study finds several species of cholesterol-metabolizing bacteria in people with lower cholesterol levels. By Allessandra DiCorato April 2, 2024 Credit: Ahmed Mohamed Rod-shaped Oscillibacter sp. bacteria take up fluorescently labeled cholesterol (here shown in green).

Disease 145
article thumbnail

Bromodomain and Extra-Terminal Domain Protein 2 in Multiple Human Diseases [Minireview]

ASPET

Bromine domain protein 2 (BRD2), a member of the Bromodomain and extraterminal domain (BET) protein family, is a crucial epigenetic regulator with significant function in various diseases and cellular processes. The central function of BRD2 is modulating gene transcription by binding to acetylated lysine residues on histones and transcription factors.

Disease 100
article thumbnail

Australia on track for unprecedented, decades-long megadroughts

Science Daily: Pharmacology News

Australia could soon see megadroughts that last for more than 20 years, according to new modelling. The researchers' bleak findings are before factoring in human impact on the climate since the Industrial Revolution. According to the scientists, the findings paint a worrying picture of future droughts in Australia that are far worse than anything in recent experience.

Research 121
article thumbnail

The FDA’s New Draft Guidance on DMCs: What to Know

Cytel

Data monitoring committees (DMCs) review ongoing clinical trial data to make recommendations regarding trial conduct based on risk-benefit. DMCs are an essential component to ensuring the integrity and safety of clinical trials. New draft guidance published by the U.S. FDA on the use of DMCs in clinical trials provides six major updates to the FDA’s expectations regarding DMC structure and practice.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

FDA Tells Congress What It Wants, What it Really Really Wants (it really really really wants a zigazig-ah)

FDA Law Blog: Biosimilars

By Sara W. Koblitz — Every year, federal agencies submit a budget request to Congress to fund various agency initiatives, and every year FDA includes a list of legislative proposals that it would like to see come out of Congress. This year is no different , and in fact some of the requests on this year’s list are repeat offenders from last year’s. And though FDA may not have gotten everything that it wanted last year, reviewing and reflecting on these lists of legislative proposals provides im

FDA 103
article thumbnail

Acorda files for bankruptcy, reveals asset sale plan

BioPharma Drive: Drug Pricing

Stalking horse bidder Merz Therapeutics could get rights to Acorda’s three marketed drugs if its $185 million proposal holds.

Marketing 117

More Trending

article thumbnail

Verve pauses base editing study after treatment side effect

BioPharma Drive: Drug Pricing

Lab test abnormalities in one study participant led the company to halt enrollment and prioritize a different version of its gene editing therapy for heart disease.

article thumbnail

First results from BREAD experiment demonstrate a new approach to searching for dark matter

Science Daily: Pharmacology News

One of the great mysteries of modern science is dark matter. We know dark matter exists thanks to its effects on other objects in the cosmos, but we have never been able to directly see it. And it s no minor thing currently, scientists think it makes up about 85% of all the mass in the universe.

Science 74
article thumbnail

Ginkgo, in search of more cell therapy tools, buys another startup

BioPharma Drive: Drug Pricing

An acquisition of Modulus Therapeutics is the latest move by Ginkgo to accumulate technologies that can help other companies develop cellular medicines.

article thumbnail

Cover Image

Chemical Biology and Drug Design

Cover Image © molekuul_be/Shutterstock.

100
100
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Roivant reveals positive immune drug data, share buyback plans

BioPharma Drive: Drug Pricing

A Pfizer drug licensed to a Roivant subsidiary surpassed expectations in a type of uveitis, while a stock purchase plan will see Roivant buy out shares owned by Sumitomo Pharma.

article thumbnail

Lessons From A Private Funding Round: Science, Relationships, And Experience

LifeSciVC

By Mike Cloonan, CEO of Sionna Therapeutics, as part of the From The Trenches feature of LifeSciVC An insightful piece on this blog following the JPM healthcare conference noted the “ refreshing burst of enthusiasm ” in the biotech sector. It’s true that venture funds raised significant capital despite numerous challenges over the past two years. And many are looking for the right investments now.

Science 66
article thumbnail

Gritstone shares fall on shaky study results for colorectal cancer vaccine

BioPharma Drive: Drug Pricing

While the company claimed its shot showed signs of working in a Phase 2 trial, the data weren’t strong enough to prove a treatment benefit.

Vaccine 67
article thumbnail

What CVS Pharmacy’s New Cost-Plus Reimbursement Approach Means for PBMs, Pharmacies, Plan Sponsors, and Prescription Prices (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. For more on acquisition cost reimbursement for pharmacies, see Sections 8.4. and 12.3.4. of our new 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. Click here to see the original post from December 2023.

article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

New tentative approval for MYLAN drug efavirenz, emtricitabine and tenofovir alafenamide

Drug Patent Watch

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.

article thumbnail

A dementia-focused VC digs past amyloid for new kinds of brain drugs

BioPharma Drive: Drug Pricing

The Dementia Discovery Fund set out to spark research into new approaches for diseases like Alzheimer’s, even as anti-amyloid therapies reach patients.

article thumbnail

New patent expiration for Sumitomo Pharma drug KYNMOBI

Drug Patent Watch

Annual Drug Patent Expirations for KYNMOBI Kynmobi is a drug marketed by Sumitomo Pharma Am and is included in one NDA. There are fourteen patents protecting this drug.

Drugs 59
article thumbnail

Synthetic Origins

Codon

In 1997, as Michael Elowitz was studying for a Ph.D. in physics at Princeton University, he had a remarkable idea: What if it were possible to build a circuit out of DNA, rather than electronics, and use it to “program” a living cell? For the next three years, working with advisor Stanislas Leibler, Elowitz labored over this synthetic gene circuit and achieved precisely that.

RNA 55
article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

New patent expiration for Merck Sharp drug DUTREBIS

Drug Patent Watch

Annual Drug Patent Expirations for DUTREBIS Dutrebis is a drug marketed by Merck Sharp Dohme and is included in one NDA. There are two patents protecting this drug.

Drugs 59
article thumbnail

How to reach the right patients in clinical trial advertising

Antidote

Digital advertising, which encompasses social media, online channels, streaming content, and more can be a powerful way to reach patients. One of the biggest avenues of reaching potential clinical trial participants through digital advertising is social media — and from the statistics, it is clear why. Not only does Facebook boast more than 3 billion users every month, but 80% of social media users are searching for health information.

article thumbnail

New patent expiration for Msd Sub drug ISENTRESS HD

Drug Patent Watch

Annual Drug Patent Expirations for ISENTRESS+HD Isentress Hd is a drug marketed by Msd Sub Merck and is included in one NDA. It is available from nine suppliers.

Drugs 59
article thumbnail

Harmony in Colour and Collaboration:A Sankranti Spectacle of Pookolam, Kite Crafting, and Team Unity

Perficient: Drug Development

Introduction: Our organisation celebrated Sankranti, an auspicious occasion that marks the sun’s entry into the northern hemisphere, with a joyful celebration that united staff members in a colourful extravaganza. We made the decision to incorporate teamwork, creativity, and traditions into this year’s celebrations in order to provide everyone an unforgettable time.

52
article thumbnail

New patent expiration for Msd Sub drug ISENTRESS

Drug Patent Watch

Annual Drug Patent Expirations for ISENTRESS Isentress is a drug marketed by Msd Sub Merck and is included in three NDAs. It is available from nine suppliers.

Drugs 59
article thumbnail

React reusable API call using Custom React Hooks

Perficient: Drug Development

Introduction Custom Hooks are reusable functions that let a React JS developer tailor and adjust a React application’s functionality. React JS version 16.8 includes them. A special JavaScript function with the prefix “use” is referred to as a “ Custom Hooks.” Using a customized Hook, retrieve information from an API. This hook will return an object with the data and an optional error message given a URL.

article thumbnail

New patent expiration for Otter Pharms drug SYMPAZAN

Drug Patent Watch

Annual Drug Patent Expirations for SYMPAZAN Sympazan is a drug marketed by Otter Pharms and is included in one NDA. It is available from one supplier.

Drugs 59
article thumbnail

Therapeutic approaches for UCPPS management: research advances, experimental targets, and future directions [Minireview]

ASPET

Urologic Chronic Pelvic Pain Syndrome (UCPPS) is a painful chronic condition with persistent pain originating from the pelvis that often leads to detrimental lifestyle changes in the affected patients. The syndrome develops in both sexes, with an estimated prevalence of 5.7% to 26.6% worldwide. This narrative review summarizes currently recommended therapies for UCPPS, followed by the latest animal and clinical research advances in the field.

Research 100
article thumbnail

New patent expiration for Aquestive drug EXSERVAN

Drug Patent Watch

Annual Drug Patent Expirations for EXSERVAN Exservan is a drug marketed by Aquestive and is included in one NDA. It is available from one supplier.

Drugs 59
article thumbnail

Biotech strategies for an uncertain world

SugarCone Biotech

Contributed by Paul Rennert There is a lot to worry about as your biotech moves from discovery work to IND filings to clinical development. Time, money and execution are daily critical issues that color every decision. Steering a steady course is the job description for every management team but so is the ability to shift course mid-stream. “This is the business we have chosen” says Hyman Roth in The Godfather, and many days that’s a familiar sentiment: “I didn’t ask who gave the order”.

FDA 59
article thumbnail

New patent for Amneal drug LYVISPAH

Drug Patent Watch

Annual Drug Patent Expirations for LYVISPAH Lyvispah is a drug marketed by Amneal and is included in one NDA. It is available from two suppliers.

Drugs 59
article thumbnail

Which pharmaceutical companies have the most drug patents in Brazil?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most patents in Brazil.

article thumbnail

New patent expiration for Indivior drug SUBOXONE

Drug Patent Watch

Annual Drug Patent Expirations for SUBOXONE Suboxone is a drug marketed by Indivior and is included in two NDAs. It is available from one supplier.

Drugs 59